Transfusion medicine (Oxford, England) · 2025
A nationwide retrospective study of the seroprevalence and risk factors of transfusion-transmissible infections among blood donors in Nigeria.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oreh Adaeze, Biyama Felix, Bozegha Tariere, Fapohunda Joshua, Mgbachi Ifeanyi, Dalyop Victoria, Elisha Joy, Olupitan Folashade, Isaiah Audu, Babalola Catherine, Malammadori Abdullahi, Agahiu Emmanuel, Kure Deborah, Imonikhe Caroline, Elesie Chinonso, Ogedegbe Ajoke E, Omokaro Ukinebo, Egbeaso Jerry, Oparah Chika, Amedu Omale, Postma Maarten, Nwagha Theresa, van Hulst Marinus
Аннотация
BACKGROUND: Blood transfusion's life-saving potential is often marred by the risks of transfusion-transmissible infections (TTIs) from blood donors, for which sub-Saharan African countries record some of the highest burdens.
AIMS: We aimed to assess the seroprevalence of HBV, HCV, HIV, and Treponema pallidum among blood donors in Nigeria, and determine the association of seropositivity with particular blood donor characteristics.
METHODS: A retrospective cross-sectional study was conducted to determine the seroprevalence of HBV, HCV, HIV, and Treponema pallidum among blood donors in 13 blood establishments in Nigeria's six geopolitical zones from January 2018 to December 2019 following screening with highly sensitive Enzyme-Linked Immunosorbent Assays. Data was collected from the country's web-based software District Health Information System, Version 2 and analysed using R Studio.
RESULTS: The overall TTI seroprevalence was 10.1%, and declined from 10.9% in 2018 to 9.4% in 2019. Male donors (AOR = 0.1; 95% CI: 0.1-0.2, p < 0.001), those aged 46-55 years (AOR = 0.8, 95% CI: 0.7-0.9, p < 0.001), and first-time donors (AOR = 0.1, 95% CI: 0.10-0.12, p < 0.001) were less likely to be seropositive; whereas paid donors (AOR = 2.3, 95% CI: 2.1-2.6, p < 0.001) and mobile blood drive donors (AOR = 1.4; 95% CI: 1.3-1.5, p < 0.001) were more likely to be seropositive.
CONCLUSION: The seroprevalence of TTIs in Nigerian blood donors is high, especially among females, paid donors, and those at mobile donation sites, emphasising the importance of targeted continuous population health education and quality donor selection towards enhancing blood safety.
AIMS: We aimed to assess the seroprevalence of HBV, HCV, HIV, and Treponema pallidum among blood donors in Nigeria, and determine the association of seropositivity with particular blood donor characteristics.
METHODS: A retrospective cross-sectional study was conducted to determine the seroprevalence of HBV, HCV, HIV, and Treponema pallidum among blood donors in 13 blood establishments in Nigeria's six geopolitical zones from January 2018 to December 2019 following screening with highly sensitive Enzyme-Linked Immunosorbent Assays. Data was collected from the country's web-based software District Health Information System, Version 2 and analysed using R Studio.
RESULTS: The overall TTI seroprevalence was 10.1%, and declined from 10.9% in 2018 to 9.4% in 2019. Male donors (AOR = 0.1; 95% CI: 0.1-0.2, p < 0.001), those aged 46-55 years (AOR = 0.8, 95% CI: 0.7-0.9, p < 0.001), and first-time donors (AOR = 0.1, 95% CI: 0.10-0.12, p < 0.001) were less likely to be seropositive; whereas paid donors (AOR = 2.3, 95% CI: 2.1-2.6, p < 0.001) and mobile blood drive donors (AOR = 1.4; 95% CI: 1.3-1.5, p < 0.001) were more likely to be seropositive.
CONCLUSION: The seroprevalence of TTIs in Nigerian blood donors is high, especially among females, paid donors, and those at mobile donation sites, emphasising the importance of targeted continuous population health education and quality donor selection towards enhancing blood safety.